Skip to main content
Thryv Holdings, Inc. (THRY)
Media and Entertainment • Communication Services
Stock AI
News & Reports
August 04, 2026 Thryv Holdings, Inc. Reports 2026 Q2 Financial Results: Navigating Transition Amidst Revenue Decline Thryv Holdings, Inc. reported a significant revenue decline in Q2 2026 as it transitions from marketing services to SaaS solutions. The company faces challenges but remains focused on enhancing client offerings and operational efficiency.
July 23, 2026 Thryv Holdings, Inc. Partners with Breesy AI to Enhance Franchise Business Growth Thryv Holdings, Inc. has partnered with Breesy AI to provide franchise businesses with critical operational insights, helping them convert leads into revenue. This integration allows businesses to analyze marketing effectiveness and improve operational efficiency, driving smarter growth in a competitive landscape.
July 21, 2026 Thryv Holdings, Inc. to Announce Q2 2026 Financial Results Thryv Holdings, Inc. will release its Q2 2026 financial results on August 4, followed by a conference call for stakeholders. The company focuses on AI-driven solutions for small businesses, enhancing their marketing capabilities and customer engagement.
July 14, 2026 Thryv Holdings, Inc. Earns Prestigious Spot on 2026 Top 100 Global Most Loved Workplaces List Thryv Holdings, Inc. ranks #53 on the 2026 Top 100 Global Most Loved Workplaces list, reflecting its commitment to employee satisfaction and a positive workplace culture. The recognition highlights Thryv's focus on diversity, collaboration, and professional growth.
July 09, 2026 Thryv Holdings, Inc. Press Release: AI Adoption Survey Reveals Growing Demand for Training Among Small Businesses Thryv Holdings' latest survey shows a significant rise in AI adoption among small businesses, reaching 66%. However, 70% of owners feel they need more training to effectively use these technologies. The findings highlight a gap between adoption and capability, emphasizing the need for targeted training resources.
April 30, 2026 Thryv Holdings Reports Strong Q1 2026 Results, Exceeding Revenue and EBITDA Guidance Thryv Holdings reported impressive Q1 2026 results, with SaaS revenue reaching $116.7 million and net income increasing to $4.5 million. Despite a drop in marketing services revenue, the company demonstrated resilience and growth potential, particularly in its SaaS segment, and provided optimistic guidance for the rest of the year.
April 30, 2026 Thryv Holdings, Inc. Reports Q1 2026 Financial Results: A Mixed Bag for SMB Solutions Thryv Holdings' Q1 2026 financial results reveal a mixed performance, with SaaS revenues growing while Marketing Services faced declines. The company's strategic focus on SaaS solutions and cost management positions it for future growth despite challenges.
April 22, 2026 Thryv Therapeutics Takes Major Leap Forward in Long QT Syndrome Treatment Thryv Therapeutics has begun patient dosing in its Wave II clinical study for THRV-1268, targeting Long QT Syndrome Type 2. The FDA has granted Fast Track Designation for the therapy, signaling significant progress in addressing this serious condition.
April 09, 2026 Thryv Holdings, Inc. Set to Release Q1 2026 Financial Results Thryv Holdings, Inc. is set to release its Q1 2026 financial results on April 30, followed by a conference call to discuss insights and strategies. As a leader in small business marketing, the company’s performance will be closely monitored by investors.
March 24, 2026 Thryv Holdings, Inc. Launches AI Lead Flow: A Game-Changer for Small Business Marketing and Sales Thryv Holdings, Inc. launches Thryv AI Lead Flow™, an innovative platform designed to streamline marketing and sales for small businesses. By integrating AI technology, it addresses common challenges like poor visibility and slow follow-ups, enabling businesses to capture and convert leads more effectively.
February 26, 2026 Thryv Holdings Reports Strong SaaS Revenue Growth and Strategic Shift Towards AI-Enabled Platform Thryv Holdings has reported a remarkable 34% growth in SaaS revenue for 2025, despite an overall revenue decline. The company is shifting towards AI-enabled solutions to enhance its SMB offerings, positioning itself for future growth.
February 26, 2026 Thryv Holdings, Inc. Reports 2025 Annual Results: A Strategic Shift in Focus Thryv Holdings, Inc. reports a strategic shift in 2025, focusing on SaaS solutions despite a decrease in overall revenue. The company aims to empower SMBs with enhanced customer engagement and operational efficiency, reflecting a positive outlook for future growth.
February 03, 2026 Thryv Holdings, Inc. to Announce Q4 and Full Year 2025 Financial Results Thryv Holdings, Inc. will announce its Q4 and full year 2025 financial results on February 26, 2026. A conference call will follow, providing insights into the company's performance and future outlook. Investors are encouraged to register in advance for participation.
January 22, 2026 Cautious Optimism for 2026: Small Businesses Voice Concerns Amid Uncertainty Thryv Holdings' survey reveals small businesses are entering 2026 with cautious optimism, facing economic uncertainties and varying perceptions of AI's impact. While some owners are hopeful for growth, many express concerns over rising costs and operational challenges.
January 13, 2026 Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study for Long QT Syndrome Type 2 Thryv Therapeutics has launched the Wave II Phase 2/3 study to evaluate THRV-1268 for Long QT Syndrome Type 2, building on promising Wave I results. This pivotal trial aims to provide new treatment options for this high-risk condition.
December 17, 2025 Thryv Therapeutics Announces Positive Phase 1 Results for THRV-1268 Thryv Therapeutics has reported positive Phase 1 trial results for THRV-1268, demonstrating significant pharmacodynamic effects in obese participants. The study suggests a favorable safety profile and potential for treating heart failure, with plans for a Phase 2a trial in 2026.
December 16, 2025 Thryv Holdings, Inc. Highlights AI Trends Driving Small Business Success in 2026 Thryv Holdings, Inc. highlights key AI trends that will boost small business success in 2026. By leveraging AI for efficiency, personalization, and data-driven strategies, SMBs can enhance their operations and compete effectively. Practical tips are also shared for maximizing AI benefits.
December 02, 2025 Thryv Therapeutics Welcomes Matt Killeen, PhD as Chief Business Officer Thryv Therapeutics has appointed Dr. Matt Killeen as Chief Business Officer to enhance its business development and strategic partnerships. With nearly 20 years of experience, he will help advance the company's promising SGK1 inhibitor pipeline, particularly in cardiometabolic diseases. His leadership comes at a pivotal time as Thryv prepares for late-stage clinical trials.
November 19, 2025 Thryv Therapeutics Appoints Amy Rudolph, PhD, to Board of Directors: A Strategic Move for Heart Failure Innovations Thryv Therapeutics has appointed Dr. Amy Rudolph to its Board of Directors, aiming to strengthen its SGK1 inhibitor pipeline for heart failure. With over 25 years in pharma, Dr. Rudolph's expertise is expected to propel Thryv's innovations forward.
November 05, 2025 Thryv Therapeutics Set to Showcase Innovations at 2025 AHA Scientific Sessions Thryv Therapeutics will present innovative research on SGK1 inhibitors at the AHA Scientific Sessions 2025, highlighting their lead compound THRV-1268's potential in treating heart failure and cardiomyopathies. The studies demonstrate its efficacy in reducing inflammation and fibrosis, promising advancements in cardiovascular care.
November 04, 2025 Thryv Holdings, Inc. Unveils AI-Driven Marketing Software for Home Services Sector Thryv Holdings, Inc. has introduced an AI-enabled marketing software tailored for home service businesses, designed to enhance visibility and drive revenue growth. This solution offers automated marketing tools and a proprietary growth framework, addressing the unique challenges faced by these businesses.
November 03, 2025 Thryv Therapeutics Set to Showcase Innovations at Upcoming Healthcare Conferences Thryv Therapeutics Inc. will showcase its innovative SGK1 inhibitor pipeline at key healthcare conferences this fall. The company aims to engage with investors and highlight advancements in precision cardiovascular medicine.
October 30, 2025 Thryv Holdings, Inc. Reports Impressive SaaS Revenue Growth in Q3 2025 Thryv Holdings, Inc. reported a 33% year-over-year increase in SaaS revenue, reaching $115.9 million in Q3 2025. The company also improved its net income significantly, showcasing strong strategic growth and customer engagement. Looking ahead, Thryv forecasts continued revenue growth for Q4 2025 and beyond.
October 30, 2025 Thryv Holdings, Inc. Reports Strong Q3 2025 Performance Amid Strategic Transition Thryv Holdings, Inc. experienced robust Q3 2025 growth, with total revenue reaching $201.5 million, primarily driven by a 33% increase in SaaS revenue. While traditional marketing services faced declines, the company's strategic shift and strong client transition reflect a promising future.
October 07, 2025 Thryv Holdings, Inc. to Announce Third Quarter 2025 Financial Results Thryv Holdings, Inc. will release its third quarter 2025 financial results on October 30, followed by a conference call for stakeholders. The results will shed light on the company's performance and growth strategies in the SMB market.
September 17, 2025 Thryv Therapeutics Secures FDA Clearance for THRV-1268, Paving the Way for Long QT Syndrome Treatment Thryv Therapeutics has secured FDA clearance for THRV-1268, enabling the Phase 2/3 WAVE II study for Long QT Syndrome Type 2. This approval highlights Thryv's commitment to innovating cardiovascular treatments and reflects investor confidence in their approach.
September 08, 2025 Thryv Therapeutics Achieves Significant Milestone with FDA IND Clearance and Promising Preclinical Results Thryv Therapeutics has achieved FDA IND clearance for THRV-1268, enabling clinical trials for heart failure and atrial fibrillation. Recent preclinical results indicate significant improvements in cardiac function, positioning THRV-1268 as a potential game-changer in cardiovascular therapies.
August 25, 2025 Thryv Therapeutics Set to Showcase Cutting-Edge Research at ESC 2025 Thryv Therapeutics is set to present groundbreaking findings on THRV-1268 at ESC 2025, showcasing its potential in treating serious cardiac issues like heart failure and Long QT Syndrome. Dr. Saumya Das will lead the presentation, highlighting the compound’s effectiveness against current treatments.
July 30, 2025 Thryv Holdings, Inc. Reports Mixed Results in 2025 Q2: A Shift Towards SaaS Thryv Holdings, Inc. reported mixed Q2 2025 results, with SaaS revenues soaring by 47.8% while traditional Marketing Services faced significant declines. The company is transitioning to focus on SaaS, indicating a strategic shift amidst a challenging economic landscape.
May 13, 2025 Thryv Therapeutics Announces Promising Clinical Results and Upcoming Investor Engagements Thryv Therapeutics has revealed promising clinical results from its Wave I study on Long QT Syndrome, showing significant QTc interval reductions with its SGK1 inhibitor, LQT-1213. The company is set to engage with investors at two major healthcare conferences in New York City to discuss its innovative therapies and future plans.
May 06, 2025 Thryv Holdings, Inc. to Engage Investors at Upcoming Conferences Thryv Holdings, Inc. will participate in two important investor conferences in May 2025, focusing on building investor relationships and sharing strategic insights. The company aims to highlight its innovative solutions for small businesses, showcasing its commitment to transparency and growth.
May 01, 2025 Thryv Holdings, Inc. Reports Q1 2025 Results: A Shift Toward SaaS Thryv Holdings, Inc. experienced a 22.4% revenue decline in Q1 2025, primarily due to challenges in Marketing Services. However, its SaaS segment thrived, achieving a 49.5% revenue increase. Strategic shifts and growth initiatives are key to navigating this transition.
May 01, 2025 Thryv Holdings Reports Strong SaaS Revenue Growth in Q1 2025 Thryv Holdings reported a 50% year-over-year increase in SaaS revenue, reaching $111.1 million in Q1 2025, despite an overall revenue decline. The company is focused on enhancing customer relationships and sustaining growth amidst its transition to a software-centric model.
April 08, 2025 Thryv Holdings, Inc. Prepares to Unveil Q1 2025 Financial Results Thryv Holdings, Inc. is set to announce its Q1 2025 financial results on May 1, 2025, before market opens. A conference call will follow at 8:30 a.m. ET for insights from management.
March 27, 2025 Thryv Therapeutics to Showcase Innovations at 2025 Piper Sandler Virtual Cardio Day Thryv Therapeutics will showcase its groundbreaking work in cardiovascular research at the 2025 Piper Sandler Virtual Cardio Day. Key executives will discuss innovative therapies targeting conditions like Long QT Syndrome and heart failure using SGK1 inhibitors.
March 11, 2025 Thryv Holdings, Inc. Announces Partnerkon 2025: A Groundbreaking Conference for Partners Thryv Holdings, Inc. has launched registration for Partnerkon 2025, an exclusive conference aimed at fostering collaboration among Thryv and Keap partners. Scheduled for April 1-3 in Scottsdale, Arizona, the event will feature industry expert sessions, keynote speeches, and networking opportunities, all designed to empower small businesses.
March 09, 2025 SWOT Analysis of Thryv Holdings, Inc. in 2025 This SWOT analysis of Thryv Holdings, Inc. in 2025 highlights its strong market presence and service offerings, while addressing challenges like client dependency and competition. Opportunities for growth through SaaS expansion and international markets are discussed, alongside threats from economic downturns and regulatory compliance.
February 27, 2025 Thryv Holdings, Inc. Reports 2024 Annual Results: A Year of Transformation Amidst Challenges Thryv Holdings, Inc. reports a challenging 2024 with a 10.1% revenue decline, driven by Marketing Services. However, growth in SaaS and strategic acquisitions, like Keap, highlight transformative efforts to support SMBs.
February 27, 2025 Thryv Holdings Reports Impressive SaaS Revenue Growth in Q4 2024 Thryv Holdings, Inc. reported a robust 41% increase in SaaS revenue for Q4 2024, totaling $104.3 million. The company achieved significant subscriber growth and improved profitability, highlighting its successful transition towards a SaaS-focused business model.
February 25, 2025 Thryv Holdings, Inc. Achieves Top 50 Ranking in G2’s 2025 Best Software Awards Thryv Holdings, Inc. has been honored in G2's 2025 Best Software Awards, ranking in the Top 50 for its innovative marketing solutions for small businesses. This recognition reflects the company's commitment to customer satisfaction and effective marketing tools.
February 20, 2025 Thryv Holdings, Inc. to Showcase Innovation at Citizens JMP Technology Conference Thryv Holdings, Inc. will participate in the Citizens JMP Technology Conference on March 3, 2025, showcasing its innovative software solutions for small businesses. The event will feature one-on-one meetings with executives and discussions on AI and automation trends shaping the future of SMB operations.
February 13, 2025 Thryv Holdings, Inc. Elevates Cameron Lessard to Vice President of Corporate Development and Strategy Thryv Holdings, Inc. has promoted Cameron Lessard to Vice President of Corporate Development and Strategy to strengthen its M&A focus. Lessard's contributions have been vital in the company's growth, including a key acquisition that expanded its SaaS client base.
February 11, 2025 Thryv Holdings and 1-800Accountant Forge New Partnership to Boost Small Business Growth Thryv Holdings has partnered with 1-800Accountant to enhance support for small businesses through expert tax consultations and advanced software solutions. This collaboration aims to help entrepreneurs grow and navigate financial complexities in 2025.
November 07, 2024 Thryv Holdings, Inc. Reports Q3 2024 Financial Results: A Mixed Outlook Amid Strategic Acquisitions Thryv Holdings, Inc. faced a mixed financial performance in Q3 2024, with a revenue decline despite growth in its SaaS segment. The company is actively pursuing strategic acquisitions to enhance its market position, even as client numbers drop significantly.
August 01, 2024 Thryv Holdings, Inc. Reports 2024 Q2 Financial Results: A Mixed Bag of Performance Thryv Holdings, Inc. reported a 10.9% revenue decline in Q2 2024, highlighting challenges in traditional marketing services while the SaaS segment saw a 24.6% increase. Management plans to enhance innovation and client retention to combat these trends.
May 02, 2024 Thryv Holdings, Inc. Q1 2024 Report: A Mixed Bag of Financial Performance Thryv Holdings, Inc. faced a challenging Q1 2024 with a 12% drop in client base and a revenue decline of nearly 5%. Despite operational changes and debt restructuring, profitability remains under pressure, prompting strategic adjustments to regain market position.

Thryv Therapeutics Set to Showcase Innovations at Upcoming Healthcare Conferences

Last updated: November 03, 2025 •
Taurigo

MONTREAL, Nov. 3, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology firm known for its pioneering work in the development of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors, has announced its participation in a series of influential healthcare investor conferences this fall. These events will provide a platform for the company to share significant updates regarding its innovative pipeline and advancements in precision cardiovascular medicine, particularly in the fields of inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies.

1. Conference Lineup

Thryv Therapeutics will engage with investors and industry stakeholders through a combination of presentations, fireside chats, and one-on-one meetings across several prominent conferences:

Wells Fargo Virtual Private Biopharma Symposium 2025

  • Format: Fireside chat and one-on-one investor meetings
  • Date: Wednesday, November 5, 2025
  • Location: Virtual

Stifel Healthcare Conference 2025

  • Format: Presentation and one-on-one investor meetings
  • Date: Thursday, November 13, 2025, from 2:30 PM to 3:15 PM EST
  • Location: Lotte New York Palace Hotel, New York, NY

Jefferies Global Healthcare Conference 2025

  • Format: Investor meetings
  • Date: Monday, November 17 to Friday, November 21, 2025
  • Location: London, UK

RBC Healthcare Private Company Conference 2025

  • Format: Fireside chat and one-on-one investor meetings
  • Date: Thursday, December 11, 2025
  • Location: Virtual

2. Focus on SGK1 Inhibitors

Thryv Therapeutics is expected to highlight its cutting-edge SGK1 inhibitor pipeline, which is a crucial component of its strategy to address significant unmet medical needs in cardiovascular health. Specifically, the company is focusing on conditions such as Long QT Syndrome, atrial fibrillation, and heart failure—disorders that pose serious risks to patients and represent substantial market opportunities.

3. Engaging the Investment Community

The company is eager to connect with the investment community during these conferences, aiming to build relationships and share insights into its clinical programs. By participating in these key industry events, Thryv Therapeutics seeks to enhance visibility among potential investors and partners, showcasing its commitment to advancing precision medicine.

4. About Thryv Therapeutics

Based in Montreal, Quebec, Canada, Thryv Therapeutics Inc. is a privately owned biotechnology company that is at the forefront of developing targeted therapies to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies. Through its innovative approach, Thryv is dedicated to improving patient outcomes with its highly selective SGK1 inhibitors.

As the healthcare sector continues to evolve, Thryv Therapeutics is positioning itself as a leader in precision cardiovascular medicine, making these upcoming conferences a pivotal moment for the company and its stakeholders.

Original press release
You may also be interested in:
Products
Resources
Legal
Company
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.